Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II dose-escalation study of QL-H118 tablets in rheumatoid arthritis
CTR20263686Phase 2Active
- Sponsor
- Nanjing Qinling Pharmaceutical Technology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of oroxylin A in rheumatoid arthritis (RA) (6 arms), sponsored by Nanjing Qinling Pharmaceutical Technology. Primary endpoints: Clinically significant changes in vital signs and physical examination from baseline, Clinically significant changes in laboratory tests and electrocardiograms from baseline and 2 more. Started Sep 2026; status: active.
02
Drugs
oroxylin A
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20263686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263686.